James R. Empfield, EVP, Drug Discovery at Xenon Pharmaceuticals Inc. (XENE), sold 118,668 shares at $30.79 ($3.6M) on 2022-03-04, disclosed to the SEC on 2022-03-08.
Open-market sale of $3.6M XENE by EVP, Drug Discovery. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.79 | 18,315 | $564K | 15.5% |
| 2 | $30.79 | 18,315 | $564K | 15.5% |
| 3 | $31.42 | 6,685 | $210K | 5.8% |
| 4 | $30.23 | 8,952 | $271K | 7.4% |
| 5 | $30.23 | 695 | $21K | 0.6% |
| 6 | $30.54 | 31,048 |
| $948K |
| 26.1% |
| 7 | $30.54 | 31,048 | $948K | 26.1% |
| 8 | $30.62 | 1,805 | $55K | 1.5% |
| 9 | $30.62 | 1,805 | $55K | 1.5% |
| Total | $30.64 avg | 118,668 | $3.6M | 100% |
| Filing → |